Intelligence / Healthtech / FDA 510(k) Clearances / Becton Dickinson and Company
Approvalsdevice cleared14 Sept 2026
Becton Dickinson and Company
14 Sept 2026: Device cleared · BD BBL Mueller Hinton II Broth (Cation-Adjusted); BD Difco Mueller Hinton Broth. Recorded in the openFDA device 510(k) data.
- Decided
- 14 Sept 2026
- Device
- BD BBL Mueller Hinton II Broth (Cation-Adjusted); BD Difco Mueller Hinton Broth
- Specialty
- Microbiology
- Country
- United States
- Location
- Sparks, MD
- Clearance type
- Traditional
- 510(k) number
- K262163
- Submitted
- 2026-06-26
What this signal means
A clearance starts commercialisation: distribution, reimbursement, software and sales hires.
- 268 added in the 30 days to 9 Nov 2026.
- Cardiovascular leads with 122 clearances, then Radiology (107).
Reach them with AOS
Find the decision makers at Becton Dickinson and Company
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this approvals signal, for your approval.
Across AOS Research
Other records for Becton Dickinson and Company in our registers.
16 OctBecton, Dickinson and Companydevice cleared · HealthtechApprovals30 SeptBecton, Dickinson And CompanyClass II recall · HealthtechQuality
More in Microbiology
FDA 510(k) Clearances
6 NovBiofire Diagnostics, LLCdevice cleared · BIOFIRE FILMARRAY Gastrointestinal 1.1 (GI1.1) Panel; BIOFIRE FILMARRAY Gastrointestinal 1.1 (GI1.1) Panel MidApprovals4 NovBioFire Defense, LLCdevice cleared · BioFire Warrior Panel Control KitApprovals4 NovBIOMERIEUX, Inc.device cleared · VITEK 2 AST-Gram Negative Polymyxin B (<= 0.25 >=16µg/mL);VITEK 2 AST-Gram Negative Imipenem (<= 0.25 >=16µg/mL);VITEK 2 AST-Gram Negative Ceftazidime Avibactam (<= 0.125 >=16µg/mL)Approvals4 NovMolecular Designsdevice cleared · SimplicityDx Panel FluA/FluB/RSVApprovals3 NovbioMérieux, Inc.device cleared · VITEK PROApprovals30 OctGenMark Diagnostics, Inc.device cleared · cobas eplex respiratory pathogen panel 3Approvals
Source: openFDA device 510(k) data, data to 9 Nov 2026. Devices FDA found substantially equivalent and cleared for the US market. Decision dates as published by FDA. AOS shows what the public record says; it does not verify or endorse the company.